[The therapeutic results and early and late toxicities of the treatment of anal canal carcinoma by radiotherapy or chemoradiotherapy].
Standard
[The therapeutic results and early and late toxicities of the treatment of anal canal carcinoma by radiotherapy or chemoradiotherapy]. / Sommer, K; Brockmann, W P; Wiegel, T; Krüll, Andreas; Hübener, K H; Birk, S.
in: STRAHLENTHER ONKOL, Jahrgang 167, Nr. 8, 8, 1991, S. 445-451.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [The therapeutic results and early and late toxicities of the treatment of anal canal carcinoma by radiotherapy or chemoradiotherapy].
AU - Sommer, K
AU - Brockmann, W P
AU - Wiegel, T
AU - Krüll, Andreas
AU - Hübener, K H
AU - Birk, S
PY - 1991
Y1 - 1991
N2 - From 1975 to 1989 114 patients with anal canal carcinoma were treated, 81 of these with radiotherapy (RT) alone and 33 with chemoradiotherapy (CRT), 80% respectively 82% of the patients were colostomy-free at the onset of therapy. RT was given to a total dose of 60 Gy in six weeks, for CRT additional simultaneous 5-fluorouracil (500 mg/m2 days 1 to 5 and 8 to 12) and mitomycin C (5 mg/m2 days 5 and 12) was administered. 67% respectively 82% of the patients had UICC stage II to IIIB disease predominantly with G2 and G3 squamous cell carcinomas. Local control after three years was 79% for the RT group vs. 82% for the CRT group. Three-year survival rate was 68% and 71%, respectively. These differences were not significant. Only for G1- compared to G3-tumors there is a significantly higher survival rate. Acute and late damage was slightly lower for the RT treatment group (77% and 25%) compared to the CRT group (79% and 30%). In both treatment groups there was one patient needing a permanent colostomy due to radiation induced proctitis. In conclusion, RT or CRT should be the primary form of treatment in patients with and canal carcinoma and abdominoperineal resection should only be performed in case of local recurrence or tumor persistence. The final decision about the indications for RT or CRT can only be made with the results of a prospective randomized trial.
AB - From 1975 to 1989 114 patients with anal canal carcinoma were treated, 81 of these with radiotherapy (RT) alone and 33 with chemoradiotherapy (CRT), 80% respectively 82% of the patients were colostomy-free at the onset of therapy. RT was given to a total dose of 60 Gy in six weeks, for CRT additional simultaneous 5-fluorouracil (500 mg/m2 days 1 to 5 and 8 to 12) and mitomycin C (5 mg/m2 days 5 and 12) was administered. 67% respectively 82% of the patients had UICC stage II to IIIB disease predominantly with G2 and G3 squamous cell carcinomas. Local control after three years was 79% for the RT group vs. 82% for the CRT group. Three-year survival rate was 68% and 71%, respectively. These differences were not significant. Only for G1- compared to G3-tumors there is a significantly higher survival rate. Acute and late damage was slightly lower for the RT treatment group (77% and 25%) compared to the CRT group (79% and 30%). In both treatment groups there was one patient needing a permanent colostomy due to radiation induced proctitis. In conclusion, RT or CRT should be the primary form of treatment in patients with and canal carcinoma and abdominoperineal resection should only be performed in case of local recurrence or tumor persistence. The final decision about the indications for RT or CRT can only be made with the results of a prospective randomized trial.
KW - Humans
KW - Aged
KW - Middle Aged
KW - Follow-Up Studies
KW - Time Factors
KW - Combined Modality Therapy
KW - Retrospective Studies
KW - Radiotherapy Dosage
KW - Neoplasm Staging
KW - Fluorouracil/administration & dosage/adverse effects
KW - Antineoplastic Agents/administration & dosage
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
KW - Anus Neoplasms/complications/drug therapy/mortality/pathology/radiotherapy
KW - Mitomycin
KW - Mitomycins/administration & dosage/adverse effects
KW - Particle Accelerators
KW - Radiation Injuries/epidemiology
KW - Humans
KW - Aged
KW - Middle Aged
KW - Follow-Up Studies
KW - Time Factors
KW - Combined Modality Therapy
KW - Retrospective Studies
KW - Radiotherapy Dosage
KW - Neoplasm Staging
KW - Fluorouracil/administration & dosage/adverse effects
KW - Antineoplastic Agents/administration & dosage
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
KW - Anus Neoplasms/complications/drug therapy/mortality/pathology/radiotherapy
KW - Mitomycin
KW - Mitomycins/administration & dosage/adverse effects
KW - Particle Accelerators
KW - Radiation Injuries/epidemiology
M3 - SCORING: Zeitschriftenaufsatz
VL - 167
SP - 445
EP - 451
JO - STRAHLENTHER ONKOL
JF - STRAHLENTHER ONKOL
SN - 0179-7158
IS - 8
M1 - 8
ER -
